Monobactams
On this page
Direct answer
Monobactams are beta-lactams with a single-ring core, and aztreonam is the only member in clinical use. It is a selective gram-negative agent, active against Enterobacterales and Pseudomonas aeruginosa while possessing no useful activity against gram-positive cocci or anaerobes. Its distinctive virtue is negligible cross-reactivity with penicillin allergy, allowing safe therapy in many beta-lactam-allergic patients.
What you must remember
- Aztreonam binds penicillin-binding protein 3 of gram-negative bacteria, disrupting septum formation during cell division; it is stable to many gram-negative beta-lactamases but not to extended-spectrum beta-lactamases.
- Spectrum: Escherichia coli, Klebsiella, Proteus, Enterobacter, Serratia, Haemophilus influenzae, Neisseria and Pseudomonas aeruginosa; zero cover of staphylococci, streptococci, enterococci, anaerobes and atypicals.
- Pharmacokinetics: not absorbed orally, given intravenously or intramuscularly, widely distributed including modest cerebrospinal fluid penetration with inflamed meninges, and eliminated mainly unchanged by the kidney requiring dose adjustment in renal impairment.
- Uses: gram-negative nosocomial infections in the beta-lactam-allergic patient, febrile neutropenia combined with a gram-positive agent, complicated urinary infection, and as a component of intra-abdominal regimens alongside metronidazole and a gram-positive drug.
- Allergy profile: IgE cross-reactivity with penicillins is minimal because the side chain differs — the recognised exception being patients sensitised to ceftazidime, whose side chain aztreonam shares.
- Adverse effects are mild — phlebitis, rash, transaminase elevation, nausea, and occasional transient neutropenia with prolonged courses; no nephrotoxicity of note.
- It carries no useful gram-positive activity, so empirical monotherapy for undifferentiated sepsis is inappropriate.
Common confusion
The recurring error is branding aztreonam a broad-spectrum beta-lactam like a carbapenem. Its single ring confers narrow, purely aerobic gram-negative activity — cover for Staphylococcus aureus or Bacteroides must come from a companion drug. The second misconception is that it is safe in every beta-lactam allergy; patients sensitised to ceftazidime may still react to aztreonam because the two molecules share an identical side chain.
Exam-focused takeaway
Theory answers should define the single-ring chemistry, state the gram-negative-only spectrum, outline pharmacokinetics and highlight the allergy advantage. Viva examiners ask when aztreonam is preferable to an aminoglycoside in the allergic patient with pseudomonal infection. MCQs test the exclusive gram-negative spectrum, renal elimination, the ceftazidime side-chain cross-reaction and its role in febrile neutropenia combinations.
Frequently asked questions
What structural feature defines a monobactam?
A single beta-lactam ring without the fused thiazolidine or dihydrothiazine ring of penicillins and cephalosporins.
Is aztreonam active against anaerobes or staphylococci?
No — it is exclusively an aerobic gram-negative agent, requiring companion drugs whenever gram-positive or anaerobic cover is needed.
Can aztreonam be used in penicillin-allergic patients?
Generally yes, as IgE cross-reactivity with penicillins is minimal; caution applies to patients with prior ceftazidime hypersensitivity, because the two drugs share the same side chain.
How is aztreonam eliminated?
Predominantly unchanged in urine by glomerular filtration, so the dosing interval must be extended in renal impairment.
Why combine aztreonam with vancomycin in febrile neutropenia?
To pair gram-negative cover with gram-positive cover in a patient unable to receive conventional beta-lactams because of allergy.